Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Devogelaer, J.P
space
  arrow  Deuxchaisnes, C. N.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Relation of Osteopenia to Glucocorticoid Replacement Therapy in Addison Disease

right arrow J.P Devogelaer, MD; J. Crabbe, MD; and C. Nagant Deuxchaisnes, MD

1 August 1994 | Volume 121 Issue 3 | Pages 235-237


TO THE EDITOR:

The interesting study by Zelissen and colleagues [1] on bone mineral density in patients with Addison disease seems to confirm our published findings, that it is the lack of adrenal androgens in patients with Addison disease rather than the glucocorticoid replacement therapy that is responsible for low bone mineral density [2, 3]. Thus, the title of their article is misleading. Furthermore, their Table 1 is somewhat confusing, particularly because of the failure to distinguish postmenopausal from premenopausal women. In our experience [2, 3] only postmenopausal women with Addison disease have a decreased bone mineral density both at the forearm and at the lumbar spine. Zelissen and colleagues' Table 2 indicates that in women, bone mass was related to plasma androstenedione levels with a correlation coefficient (called a regression coefficient) reaching statistical significance for the femoral neck only. Hydrocortisone or cortisone treatment seems an unlikely cause of osteopenia because the daily doses did not exceed 37.5 mg of cortisone acetate (that is, 20 to 30 mg of hydrocortisone). These doses are in the range used to treat adults with Addison disease, as well as levels recognized by pediatric endocrinologists to have no detrimental effect on statural growth (10 to 20 mg/m2 per 24 h) while preventing undue virilization in children with the congenital adrenogenital syndrome [4, 5]. We believe that the osteopenia is not caused by glucocorticoid replacement therapy by itself. The deficient production of adrenal androgens in patients with Addison disease leads to osteopenia in postmenopausal women with Addison disease who are not receiving hormonal replacement therapy. In premenopausal women with the disease, however, bone mass is maintained because of ovarian estrogen production. Other factors, such as concomitant diabetes mellitus or associated autoimmune endocrinopathies or a history of tuberculosis, which lead to immobilization and inactivity, could be partly responsible for a low bone mineral density in men, as we have previously shown [2].


References
space
up arrowTop
dotReferences

1. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med. 1994; 120:207-10.

2. Devogelaer JP, Crabbe J, Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J. 1987; 294:798-800.

3. Devogelaer JP, Crabbe J, Nagant de Deuxchaisnes C. Trabecular bone mass in postmenopausal addisonians: a clue to postmenopausal osteoporosis? In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Viborg: Norhaven; 1987:623-4.

4. Winter JS, Couch RM. Modern medical therapy of congenital adrenal hyperplasia. Ann N Y Acad Sci. 1985; 458:165-73.

5. Migeon CJ. Diagnosis and treatment of adrenogenital disorders. In: DeGroot LJ, ed. Endocrinology. 2d ed. Philadelphia: W.B. Saunders; 1989:1676-704.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Devogelaer, J.P
space
  arrow  Deuxchaisnes, C. N.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online